WASHINGTON – US biotech firm Moderna won’t seek an emergency use authorization for its coronavirus vaccine before November 25, its CEO told the Financial Times on Wednesday.
The news deals a blow to President Donald Trump’s hopes of having an injection ready before the election to give his campaign a much-needed boost.
“November 25 is the time we will have enough safety data to be able to put into an EUA file that we would send to the FDA (Food and Drug Administration) — assuming that the safety data is good, i.e. a vaccine is deemed to be safe,” Stephane Bancel said.
Trump, whose approval has taken a hit over his handling of the COVID-19 crisis, has frequently hinted a vaccine could be ready before the November 3 vote.
This has raised concern among experts that his administration may attempt to interfere with the regulatory process for political reasons.
Moderna’s vaccine is one of 11 experimental vaccines in final stage trials.
Another is being developed by Pfizer, whose CEO Albert Bourla has taken the position that his company may have a clear answer about whether their shot works by October. (AFP)
